Trial reportInvestigative ophthalmology & visual science2016
Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
Trial report in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss
Evolution of Body Mass Index in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment. Retrospective and Prospective Study
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH).Neurosurgical review · 2021Pooled it
- Visual Field Pointwise Analysis of the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT).Translational vision science & technology · 2023Trial
- Article
- Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease management.Journal of neurology · 2025Article
- Factors associated with vision loss in idiopathic intracranial hypertension patients with severe papilledema.Eye (London, England) · 2025Article
- The Psychological and Cognitive Landscape of Adult Idiopathic Intracranial Hypertension: A Scoping Review.Neurology. Clinical practice · 2024Article
- Idiopathic intracranial hypertension in Asians: a retrospective dual-center study.The journal of headache and pain · 2024Article
- Longitudinal optical coherence tomography indices in idiopathic intracranial hypertension.Scientific reports · 2024Article
- Interpretation of the Visual Field in Neuro-ophthalmic Disorders.Current neurology and neuroscience reports · 2024Review
- MRI features of idiopathic intracranial hypertension are not prognostic of visual and headache outcome.The journal of headache and pain · 2023Article
- Archetypal analysis of longitudinal visual fields for idiopathic intracranial hypertension patients presenting in a clinic setting.PLOS digital health · 2023Article
- Management of recurrent cerebrospinal fluid leak, current practices and open challenges. A systematic literature review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2023Review
- Course and Predictors of Visual Outcome of Idiopathic Intracranial Hypertension.Neuro-ophthalmology (Aeolus Press) · 2022Article
- Unsupervised Machine Learning Identifies Quantifiable Patterns of Visual Field Loss in Idiopathic Intracranial Hypertension.Translational vision science & technology · 2021Article
- Artifactual Visual Field Defects Identified on Technically "Reliable" Visual Field Studies in a Neuro-Ophthalmology Practice.Eye and brain · 2021Article
- Modeling a potential SANS countermeasure by experimental manipulation of the translaminar pressure difference in mice.NPJ microgravity · 2020Article
- Decreased retinal nerve fiber layer thickness in patients with cerebral venous thrombosis.BMC ophthalmology · 2019Article
- Ganglion Cell Complex Analysis as a Potential Indicator of Early Neuronal Loss in Idiopathic Intracranial Hypertension.Neuro-ophthalmology (Aeolus Press) · 2019Article
- Diffusion tensor imaging of the optic disc in idiopathic intracranial hypertension.Neuroradiology · 2018Article
- Characterization of Retinal Ganglion Cell and Optic Nerve Phenotypes Caused by Sustained Intracranial Pressure Elevation in Mice.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) showed that acetazolamide provided a modest, significant improvement in mean deviation (MD). Here, we further analyze visual field changes over the 6-month study period.
methodsOf 165 subjects with mild visual loss in the IIHTT, 125 had perimetry at baseline and 6 months. We evaluated pointwise linear regression of visual sensitivity versus time to classify test locations in the worst MD (study) eye as improving or not; pointwise changes from baseline to month 6 in decibels; and clinical consensus of change from baseline to 6 months.
resultsThe average study eye had 36 of 52 test locations with improving sensitivity over 6 months using pointwise linear regression, but differences between the acetazolamide and placebo groups were not significant. Pointwise results mostly improved in both treatment groups with the magnitude of the mean change within groups greatest and statistically significant around the blind spot and the nasal area, especially in the acetazolamide group. The consensus classification of visual field change from baseline to 6 months in the study eye yielded percentages (acetazolamide, placebo) of 7.2% and 17.5% worse, 35.1% and 31.7% with no change, and 56.1% and 50.8% improved; group differences were not statistically significant.
conclusionsIn the IIHTT, compared to the placebo group, the acetazolamide group had a significant pointwise improvement in visual field function, particularly in the nasal and pericecal areas; the latter is likely due to reduction in blind spot size related to improvement in papilledema. (ClinicalTrials.gov number, NCT01003639.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.